

WHAT IS CLAIMED IS:

1. A method of treating a patient with liver disease comprising administering to said patient a cyclooxygenase-2 inhibiting amount of a selective inhibitor of cyclooxygenase-2.
2. The method of Claim 1, wherein the liver disease is an inflammatory liver disorder.
3. The method of Claim 2, wherein the inflammatory liver disorder is selected from the group consisting of chronic viral hepatitis B, chronic viral hepatitis C, alcoholic liver injury, primary biliary cirrhosis, autoimmune hepatitis, nonalcoholic steatohepatitis, and liver transplant rejection.
4. The method of Claim 3, wherein the selective inhibitor of cyclooxygenase-2 is 4-[5-(4-chlorophenyl)-3-(trifluoromethyl)-1H-pyrazol-1-yl]benzenesulfonamide.
5. The method of Claim 3, wherein the selective inhibitor of cyclooxygenase-2 is 4-[5-(4-methylphenyl)-3-(trifluoromethyl)-1H-pyrazol-1-yl]benzenesulfonamide.
6. The method of Claim 3, wherein the selective inhibitor of cyclooxygenase-2 directly inhibits the enzyme cyclooxygenase-2 and also inhibits the synthesis of cyclooxygenase-2 protein.
7. A method of treating a patient with a virus-caused liver disease comprising administering to said patient a cyclooxygenase-2 inhibiting amount of selective inhibitor of cyclooxygenase-2 and therapeutic amount(s) of anti-viral drug(s).

8. The method of Claim 7, wherein the liver disease is selected from the group consisting of chronic viral hepatitis B and chronic viral hepatitis C.

Sub C2
9. The method of Claim 8, wherein the selective inhibitor of cyclooxygenase-2 is 4-[5-(4-chlorophenyl)-3-(trifluoromethyl)-1H-pyrazol-1-yl]benzenesulfonamide.

10. The method of Claim 8, wherein the selective inhibitor of cyclooxygenase-2 is 4-[5-(4-methylphenyl)-3-(trifluoromethyl)-1H-pyrazol-1-yl]benzenesulfonamide.

11. The method of Claim 8, wherein the selective inhibitor of cyclooxygenase-2 directly inhibits the enzyme cyclooxygenase-2 and also inhibits the synthesis of cyclooxygenase- protein.

12. A selective inhibitor of cyclooxygenase-2 which directly inhibits the enzyme cyclooxygenase-2 and which also inhibits the synthesis of cyclooxygenase-2 protein.

13. The selective inhibitor of cyclooxygenase-2 of Claim 12 which contains phenyl group with two or more substituents on the phenyl group selected from the group consisting of hydroxy and C₁₋₄-alkoxy.

14. The selective inhibitor of Claim 13 which is selected from the group consisting of 4-[5-(4-methyl-3-[(2,3-hydroxy)phenoxy]methyl]-1H-pyrazol-1-yl]benzenesulfonamide and 4-methyl-5-(4-methylsulfonyl)phenyl-2-[(2,3-hydroxyphenoxy)methyl]oxazole and the corresponding compounds where methoxy or ethoxy replace hydroxy.

15. The selective inhibitor of cyclooxygenase-2 of Claim 14 which is 4-[5-methyl-3-[(2,3-hydroxy)phenoxy]methyl]-1H-pyrazol-1-yl]benzenesulfonamide.

16. The selective inhibitor of cyclooxygenase-2 of Claim 14 which is 4-methyl-5-(4-methylsulfonyl)phenyl-2-[(2,3-hydroxyphenoxy) methyl]oxazole.

add
BB